Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of December 2024. The document serves as a transaction notification regarding a specific equity event involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single transaction event.
| Metric | Value |
|---|---|
| Transaction Type | Grant of options over Ordinary Shares |
| Instrument | Ordinary Shares of 31 1/2 pence each (ISIN: GB00BN7SWP63) |
| Volume | 822 options |
| Price | £11.27 |
| Date of Transaction | November 28, 2024 |
| Place of Transaction | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an initial notification of an option grant under the Company's Share Save Plan 2022 to Sally Jackson, SVP, Global Communications and CEO Office.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a compliance notification for a specific share-based compensation event.
Investor Verification Points
- Verify the terms of the Share Save Plan 2022 to understand the vesting schedule and exercise conditions for the 822 options granted.
- Confirm the market price of GSK Ordinary Shares on November 28, 2024, to assess the strike price relative to the market value at the time of grant.
- Review subsequent filings to track the exercise or expiration of these options.